Brief: Newron Pharmaceuticals H1 Net Loss Widens To EUR 14.0 Mln
Sept 12 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* H1 NET LOSS OF EUR 14.0 MILLION, COMPARED TO EUR 7.6 MILLION IN SAME PERIOD IN 2018
Source text for Eikon: ID:nTENqgyzda
Further company coverage: NWRN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study